APTEEUS is a biotech expert in drug discovery and repositioning in the field of rare monogenic diseases. We are particularly interested in pathologies whose medical need is significant and largely unmet. Our technology allows us to conduct individualized research projects in a few months and identify new drug candidates among all molecules already used in humans, in collaboration with patient organizations, physicians and academic and industrial partners. Our innovative activity, which is at odds with the traditional drug discovery approach, aims to achieve a rapid and significant social impact.
OPERANDO is the biomedical research program in place for collecting cutaneous biopsies from patients in order to isolate the cells “model” of the pathology.
evidenceFactory is the processes we use to measure, in vitro, the causal defects of the symptoms. Based on cell imaging and mass spectrometry, they are systematically miniaturized and automated to quickly test several thousand molecules.
TEE Library is our proprietary collection of molecules approved for human use and enriched daily that we test in every new screen.
Since March 2020, we have been working on the repositioning of a drug against CoViD19,…
We are happy to find Apteeus’ commitments among the 8 recommendations of Rare2030: establish partnerships…
Dr. Terence Beghyn
Pharm.D & PhD in Medicinal Chemistry
Terence co-founded Apteeus after a career as an assistant Professor at the University of Lille. Passionate about drug discovery technologies, he now puts his expertise at the service of patients with orphan diseases. Terence is President of Apteeus.
Professor Benoit DEPREZ
Professor of Pharmacy
Benoit began his career in two biotech companies by leading the chemistry and drug discovery teams. Returning to the University in 2006, he set up a drug discovery laboratory at the Institut Pasteur de Lille, which was labelled by INSERM. Benoit is Scientific Director of the Institut Pasteur de Lille. He co-founded Apteeus and is strategic advisor.